Full Press Release Details
GAITHERSBURG, Md.,April 29, 2026/PRNewswire/ -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the event and replay are as follows:
| Conference call details: | |
| Date: | May 6, 2026 |
| Time: | 8:30 a.m. ET |
| URL to register phone: | Register Here |
| Dial-in number: | (888) 880-3330 (U.S.) or |
| (+1) (646) 357-8766 (International) | |
| Webcast: | ir.novavax.com/events |
Conference call details:
Date:
May 6, 2026
Time:
8:30 a.m. ET
URL to register phone:
Register Here
Dial-in number:
(888) 880-3330 (U.S.) or
(+1) (646) 357-8766 (International)
Webcast:
ir.novavax.com/events
• Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
• Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
| Replay details: | |
| Date: | Available starting at 11:30 a.m. ET, May 6, 2026, until 11:59 p.m. ET, May 13, 2026 |
| Dial-in number: | (800) 770-2030 (U.S.) or |
| (+1) (609) 800-9909 (International) | |
| Passcode: | 1309751# |
| Webcast: | ir.novavax.com/events, until June 6, 2026 |
Replay details:
Date:
Available starting at 11:30 a.m. ET, May 6, 2026, until 11:59 p.m. ET, May 13, 2026
Dial-in number:
(800) 770-2030 (U.S.) or
(+1) (609) 800-9909 (International)
Passcode:
1309751#
Webcast:
ir.novavax.com/events, until June 6, 2026
About NovavaxNovavax, Inc. (Nasdaq:NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M®adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visitnovavax.comandLinkedInfor more information.
Contacts:
InvestorsJim Kelly844-668-2829[email protected]
MediaYvonne Sprow844-264-8571[email protected]
SOURCE Novavax, Inc.